RecruitingPhase 2NCT07289763
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment
75 participants
Start Date
Dec 31, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria3
- Age 18-75 years, regardless of gender;
- Weight ≥40.0 kg at screening;
- Diagnosed as primary membranous nephropathy through kidney biopsy.
Exclusion Criteria5
- Secondary membranous nephropathy.
- Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.
- Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.
- Subjects who have a malignant tumor or a history of malignant tumor
- Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSHR-2173 injection
SHR-2173 injection, with a total of 8 administrations
DRUGSHR-2173 injection
SHR-2173 injection, with a total of 16 administrations
DRUGSHR-2173 injection
SHR-2173 injection , with a total of 32 administrations
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07289763
Related Trials
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT0655726518 locations
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT0720427593 locations
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
NCT0696280093 locations
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT0757174621 locations
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT0647019121 locations